Strategic partnerships Nanoscope is actively expanding manufacturing and commercialization capabilities with Catalent and McKesson, signaling readiness for large-scale distribution and potential co-marketing opportunities in the US market.

Regulatory momentum Lead program MCO-010 is moving toward a potential FDA approval via rolling BLA submission, supported by Fast Track and Orphan Drug designations, which could shorten time to market and create early access sales prospects.

One-time therapy MCO-010 is positioned as a one-time, in-office injection that may reduce ongoing treatment costs and logistics for clinics, suggesting a compelling value proposition for ophthalmology practices and payer negotiations.

Expansion pipeline A diversified IND-ready pipeline including LCA and geographic atrophy programs, plus a planned Phase 3 in RP for 2025, indicates multiple cross-sell opportunities and longer-term partnerships across retinal diseases.

Speaker and events Active participation in ARVO and Eyecelerator events, along with press announcements, provides ongoing opportunities to engage KOLs, secure speaking slots, and accelerate visibility with potential customers and distributors.